Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Expenses (2016 - 2025)

Ani Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $212.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 8.9% year-over-year to $212.3 million; the TTM value through Dec 2025 reached $772.3 million, up 25.82%, while the annual FY2025 figure was $772.3 million, 25.82% up from the prior year.
  • Operating Expenses for Q4 2025 was $212.3 million at Ani Pharmaceuticals, up from $191.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $212.3 million in Q4 2025 and bottomed at $51.5 million in Q1 2021.
  • The 5-year median for Operating Expenses is $109.0 million (2023), against an average of $121.7 million.
  • The largest annual shift saw Operating Expenses dropped 10.66% in 2021 before it soared 62.55% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $84.7 million in 2021, then increased by 9.17% to $92.4 million in 2022, then skyrocketed by 35.19% to $124.9 million in 2023, then skyrocketed by 56.05% to $195.0 million in 2024, then grew by 8.9% to $212.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Operating Expenses are $212.3 million (Q4 2025), $191.6 million (Q3 2025), and $197.5 million (Q2 2025).